NO20053112L - Peptider som malsoker tumor- og endotelceller, sammensetninger og anvendelser av slike. - Google Patents

Peptider som malsoker tumor- og endotelceller, sammensetninger og anvendelser av slike.

Info

Publication number: NO20053112L
Authority: NO; Norway
Prior art keywords: peptides; compositions; endothelial cells; tumor; target tumor
Prior art date: 2002-11-25

Application number

NO20053112A

Other languages

English (en)

Norwegian (no)

Other versions

NO20053112D0 (no

Inventor

Robert J Ternansky

Andrew Mazar

Patricia L Gladstone

Amy L Allan

Fernando Donate

Won Hyung Yoon

Graham Parry

Original Assignee

Attenuon Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-25

Filing date

2005-06-24

Publication date

2005-08-05

2005-06-24 Application filed by Attenuon Llc filed Critical Attenuon Llc

2005-06-24 Publication of NO20053112D0 publication Critical patent/NO20053112D0/no

2005-08-05 Publication of NO20053112L publication Critical patent/NO20053112L/no

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
206010028980 Neoplasm Diseases 0.000 title abstract 2
210000002889 endothelial cell Anatomy 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
210000004881 tumor cell Anatomy 0.000 title abstract 2
MMHDBUJXLOFTLC-WOYTXXSLSA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2s)-1-acetylpyrrolidine-2-carbonyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-sulfanylpropanoyl]amino]butanediamide Chemical compound CC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O)CC1=CN=CN1 MMHDBUJXLOFTLC-WOYTXXSLSA-N 0.000 abstract 1
206010027476 Metastases Diseases 0.000 abstract 1
108010011755 acetyl-prolyl-histidyl-seryl-cysteinyl-asparaginamide Proteins 0.000 abstract 1
230000033115 angiogenesis Effects 0.000 abstract 1
230000001772 anti-angiogenic effect Effects 0.000 abstract 1
230000002001 anti-metastasis Effects 0.000 abstract 1
230000000259 anti-tumor effect Effects 0.000 abstract 1
239000000969 carrier Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000009401 metastasis Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000003053 toxin Substances 0.000 abstract 1
231100000765 toxin Toxicity 0.000 abstract 1
108700012359 toxins Proteins 0.000 abstract 1
230000004614 tumor growth Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)

NO20053112A 2002-11-25 2005-06-24 Peptider som malsoker tumor- og endotelceller, sammensetninger og anvendelser av slike. NO20053112L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US42917402P	2002-11-25	2002-11-25
US47553903P	2003-06-02	2003-06-02
PCT/US2003/037895 WO2004063213A2 (fr)	2002-11-25	2003-11-25	Peptides ciblant des cellules tumorales et endotheliales, compositions et leurs utilisations

Publications (2)

Publication Number	Publication Date
NO20053112D0 NO20053112D0 (no)	2005-06-24
NO20053112L true NO20053112L (no)	2005-08-05

Family

ID=32397181

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20053111A NO20053111L (no)	2002-11-25	2005-06-24	Peptider som inhiberer angiogenese, cellemigrering, celleinvasjon og celleproliferering.
NO20053112A NO20053112L (no)	2002-11-25	2005-06-24	Peptider som malsoker tumor- og endotelceller, sammensetninger og anvendelser av slike.

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
NO20053111A NO20053111L (no)	2002-11-25	2005-06-24	Peptider som inhiberer angiogenese, cellemigrering, celleinvasjon og celleproliferering.

Country Status (14)

Country	Link
US (2)	US20050020810A1 (fr)
EP (2)	EP1569678A4 (fr)
JP (2)	JP2006514116A (fr)
KR (2)	KR20050096917A (fr)
AU (2)	AU2003298726A1 (fr)
BR (2)	BR0316550A (fr)
CA (2)	CA2507045A1 (fr)
EA (2)	EA200500870A1 (fr)
HR (2)	HRP20050585A2 (fr)
MX (2)	MXPA05005469A (fr)
NO (2)	NO20053111L (fr)
NZ (2)	NZ540363A (fr)
PL (2)	PL377763A1 (fr)
WO (2)	WO2004047771A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003298726A1 (en) *	2002-11-25	2004-08-10	Attenuon Llc	Peptides which target tumor and endothelial cells, compositions and uses thereof
EP1766405A1 (fr) *	2004-05-21	2007-03-28	MDS Inc. doing Business Through Its MDS Pharma Services Division	Procédé permettant de quantifier les propriétés de fixation cellulaire d'un dispositif médical
US20060078535A1 (en) *	2004-10-13	2006-04-13	The Regents Of The University Of Michigan	Anticancer compounds and methods
KR20070100832A (ko) *	2005-02-01	2007-10-11	아테뉴온, 엘엘씨	항혈관신생 ｐｈｓｃｎ 펩티드를 함유하는 조성물
US20080261892A1 (en)	2005-02-01	2008-10-23	Ternansky Robert J	Acid Addition Salts of Ac-Phscn-Nh2
AU2006350707A1 (en) *	2006-11-08	2008-05-15	Chongxi Yu	Transdermal delivery systems of peptides and related compounds
AU2016213759B2 (en) *	2006-11-08	2018-03-29	Chongxi Yu	Transdermal delivery systems of peptides and related compounds
TWI568447B (zh)	2009-05-08	2017-02-01	上海泰飛爾生化技術有限公司	具有快速透皮速度的多肽及多肽相關化合物的前藥組合物
KR101228668B1 (ko)	2010-09-17	2013-01-31	가톨릭대학교 산학협력단	혈관신생 억제 활성을 갖는 펩타이드 및 이의 용도
DE112012002570B4 (de)	2011-06-23	2023-11-23	Board Of Regents, The University Of Texas System	Identifizieren von Peptiden auf der Einzelmolekülebene
US11435358B2 (en)	2011-06-23	2022-09-06	Board Of Regents, The University Of Texas System	Single molecule peptide sequencing
CN102417540A (zh) *	2011-11-21	2012-04-18	中国药科大学	一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
EP2846847B1 (fr) *	2012-05-11	2020-03-25	C.P. Medical Corporation	Traitements à base d'hydrogel biocompatible pour traiter un décollement de la rétine
IN2014KN02990A (fr)	2012-06-04	2015-05-08	Suncor Energy Inc
ES2664411T3 (es)	2013-03-15	2018-04-19	Suncor Energy Inc.	Composiciones herbicidas
JP5970439B2 (ja) *	2013-09-20	2016-08-17	チョンシーユー	ペプチド及び関連化合物の経皮送達システム
EP3543703A1 (fr)	2014-09-15	2019-09-25	Board of Regents, The University of Texas System	Séquençage amélioré des peptides d'une seule molécule
WO2020014586A1 (fr)	2018-07-12	2020-01-16	Board Of Regents, The University Of Texas System	Détection dans le voisinage moléculaire par des oligonucléotides
AU2020222515B2 (en)	2019-02-15	2025-10-09	Nutrien Ag Solutions (Canada) Inc.	The use of protoporphyrin IX derivatives to improve the health of plants

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3845770A (en) *	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en) *	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4440788A (en) *	1980-05-13	1984-04-03	Mitsubishi Chemical Industries, Limited	Cysteine derivatives
WO1981003330A1 (fr)	1980-05-13	1981-11-26	Mitsubishi Chem Ind	Derives de la cysteine et leur production
US4394519A (en) *	1982-01-19	1983-07-19	Research Corporation	Amino acid blocking agents
GB8504253D0 (en) *	1985-02-19	1985-03-20	Ici Plc	Electrostatic spraying apparatus
US4683202A (en) *	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
DE3815221C2 (de) *	1988-05-04	1995-06-29	Gradinger F Hermes Pharma	Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5091176A (en) *	1988-11-02	1992-02-25	W. R. Grace & Co.-Conn.	Polymer-modified peptide drugs having enhanced biological and pharmacological activities
US5443816A (en) *	1990-08-08	1995-08-22	Rhomed Incorporated	Peptide-metal ion pharmaceutical preparation and method
US5229366A (en) *	1990-10-23	1993-07-20	Fuji Photo Film Co., Ltd.	Peptide-containing polyethylene glycol derivatives and application thereof
US5149801A (en) *	1990-11-21	1992-09-22	The Regents Of The University Of California	Boronated porphyrin compounds
US5561220A (en) *	1991-02-08	1996-10-01	Diatech, Inc.	Technetium-99m labeled peptides for imaging inflammation
US5698155A (en) *	1991-05-31	1997-12-16	Gs Technologies, Inc.	Method for the manufacture of pharmaceutical cellulose capsules
US5556609A (en) *	1992-02-20	1996-09-17	Rhomed Incorporated	YIGSR peptide radiopharmaceutical applications
US5608110A (en) *	1993-06-15	1997-03-04	Bracco International B.V.	Heteroatom-bearing ligands and metal complexes thereof
US5639725A (en) *	1994-04-26	1997-06-17	Children's Hospital Medical Center Corp.	Angiostatin protein
ES2177771T3 (es) *	1995-03-14	2002-12-16	Siemens Ag	Dispositivo atomizador ultrasonico con unidad desmontable de dosificacion de precision.
ZA962077B (en) *	1995-03-14	1997-03-26	Siemens Ag	Ultrasonic atomizer device with removable precision dosating unit
US5618513A (en) *	1995-06-07	1997-04-08	Mallinckrodt Medical, Inc.	Method for preparing radiolabeled peptides
MY147327A (en) *	1995-06-29	2012-11-30	Novartis Ag	Somatostatin peptides
JP2001501600A (ja) *	1996-09-10	2001-02-06	ザバーナムインスティテュート	腫瘍ホーミング分子、それに由来する結合体、およびその使用方法
US6331409B1 (en) *	1996-11-21	2001-12-18	The Regents Of The University Of Michigan	Methods and compositions for wound healing
US6025150A (en) *	1996-11-21	2000-02-15	The Regents Of The University Of Michigan	Methods and compositions for wound healing
US6001965A (en) *	1996-11-21	1999-12-14	The Regents Of The University Of Michigan	Anticancer compounds and methods
DE69824352T2 (de) *	1997-01-14	2005-06-30	Kaneka Corp.	Verfahren zur herstellung von cystein derivaten
US5994309A (en) *	1997-07-25	1999-11-30	Angstrom Pharmaceuticals, Inc.	Anti-invasive and anti-angiogenic compositions and methods
JP2001516055A (ja) *	1997-09-10	2001-09-25	ザバーナムインスティチュート	腫瘍中の血管形成血管系にホーミングする分子を同定する方法
NZ504021A (en) *	1997-10-17	2003-04-29	Systemic Pulmonary Delivery Lt	Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
US6468974B1 (en) *	1998-08-14	2002-10-22	The Administrators Of The Tulane Educational Fund	Compounds having growth hormone releasing activity
CA2435320C (fr)	2001-01-18	2008-06-03	The Regents Of The University Of Michigan	Compositions et methodes destinees a l'utilisation de fragments de fibronectine dans le diagnostic du cancer
AU2003298726A1 (en)	2002-11-25	2004-08-10	Attenuon Llc	Peptides which target tumor and endothelial cells, compositions and uses thereof

2003
- 2003-11-25 AU AU2003298726A patent/AU2003298726A1/en not_active Abandoned
- 2003-11-25 WO PCT/US2003/038175 patent/WO2004047771A2/fr not_active Ceased
- 2003-11-25 JP JP2005510345A patent/JP2006514116A/ja active Pending
- 2003-11-25 PL PL377763A patent/PL377763A1/pl not_active Application Discontinuation
- 2003-11-25 WO PCT/US2003/037895 patent/WO2004063213A2/fr not_active Ceased
- 2003-11-25 JP JP2005512876A patent/JP2006515866A/ja active Pending
- 2003-11-25 NZ NZ540363A patent/NZ540363A/en unknown
- 2003-11-25 CA CA002507045A patent/CA2507045A1/fr not_active Abandoned
- 2003-11-25 NZ NZ540889A patent/NZ540889A/en not_active IP Right Cessation
- 2003-11-25 MX MXPA05005469A patent/MXPA05005469A/es not_active Application Discontinuation
- 2003-11-25 EA EA200500870A patent/EA200500870A1/ru unknown
- 2003-11-25 BR BR0316550-7A patent/BR0316550A/pt not_active IP Right Cessation
- 2003-11-25 CA CA002506813A patent/CA2506813A1/fr not_active Abandoned
- 2003-11-25 HR HR20050585A patent/HRP20050585A2/xx not_active Application Discontinuation
- 2003-11-25 HR HR20050584A patent/HRP20050584A2/hr not_active Application Discontinuation
- 2003-11-25 MX MXPA05005545A patent/MXPA05005545A/es unknown
- 2003-11-25 EP EP03796483A patent/EP1569678A4/fr not_active Withdrawn
- 2003-11-25 PL PL377701A patent/PL377701A1/pl not_active Application Discontinuation
- 2003-11-25 AU AU2003297609A patent/AU2003297609A1/en not_active Abandoned
- 2003-11-25 KR KR1020057009356A patent/KR20050096917A/ko not_active Withdrawn
- 2003-11-25 EP EP03812058A patent/EP1594521A4/fr not_active Withdrawn
- 2003-11-25 US US10/722,843 patent/US20050020810A1/en not_active Abandoned
- 2003-11-25 EA EA200500871A patent/EA200500871A1/ru unknown
- 2003-11-25 BR BR0316523-0A patent/BR0316523A/pt not_active IP Right Cessation
- 2003-11-25 US US10/723,144 patent/US7517855B2/en not_active Expired - Fee Related
- 2003-11-25 KR KR1020057009447A patent/KR20050097494A/ko not_active Withdrawn
2005
- 2005-06-24 NO NO20053111A patent/NO20053111L/no not_active Application Discontinuation
- 2005-06-24 NO NO20053112A patent/NO20053112L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2004063213A2 (fr)	2004-07-29
HRP20050584A2 (hr)	2006-04-30
AU2003298726A1 (en)	2004-08-10
KR20050096917A (ko)	2005-10-06
JP2006514116A (ja)	2006-04-27
EA200500871A1 (ru)	2006-04-28
US20040162239A1 (en)	2004-08-19
BR0316550A (pt)	2005-10-04
NO20053112D0 (no)	2005-06-24
MXPA05005545A (es)	2005-10-18
EP1594521A4 (fr)	2008-01-09
PL377701A1 (pl)	2006-02-06
NO20053111L (no)	2005-08-24
EA200500870A1 (ru)	2006-04-28
NO20053111D0 (no)	2005-06-24
WO2004047771A3 (fr)	2005-09-15
WO2004047771A2 (fr)	2004-06-10
WO2004063213A3 (fr)	2005-03-03
NZ540363A (en)	2007-11-30
PL377763A1 (pl)	2006-02-20
MXPA05005469A (es)	2005-09-08
HRP20050585A2 (en)	2006-02-28
US7517855B2 (en)	2009-04-14
US20050020810A1 (en)	2005-01-27
EP1569678A2 (fr)	2005-09-07
JP2006515866A (ja)	2006-06-08
BR0316523A (pt)	2005-10-18
EP1594521A2 (fr)	2005-11-16
AU2003297609A1 (en)	2004-06-18
CA2506813A1 (fr)	2004-07-29
KR20050097494A (ko)	2005-10-07
EP1569678A4 (fr)	2008-01-02
NZ540889A (en)	2008-09-26
CA2507045A1 (fr)	2004-06-10

Publication	Publication Date	Title
NO20053112L (no)	2005-08-05	Peptider som malsoker tumor- og endotelceller, sammensetninger og anvendelser av slike.
CA2541438C (fr)	2013-11-26	Modulation de la synthese et de la degradation de l'hyaluronane dans le cadre du traitement de maladies
CY1122346T1 (el)	2021-01-27	Μονοκλωνα αντισωματα εναντι tης κλαουδινης 18 για τη θεραπεια του καρκινου
MY140710A (en)	2010-01-15	Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
CY1121132T1 (el)	2019-12-11	ΠΛΗΡΩΣ-ΑΝΘΡΩΠΙΝΑ ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ANTI-vap-1
TWI265927B (en)	2006-11-11	Novel compounds as NS3-serine protease inhibitors of hepatitis C virus
CY1121519T1 (el)	2020-05-29	Καθαρισμος της υδουρονικης-2-σουλφατασης
MX355255B (es)	2018-04-11	Variantes de fc y métodos para su producción.
MY145081A (en)	2011-12-15	Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
EA200801571A1 (ru)	2010-02-26	Композиции, содержащие молекулы ctl4-ig, и способы их получения
EA200801842A1 (ru)	2009-02-27	Антитела против бета-амилоидного пептида
MX2012012119A (es)	2012-12-17	Produccion de proteinas heteromultimericas.
EA201390156A1 (ru)	2014-01-30	ПРОИЗВОДСТВО ИНТЕР-АЛЬФА-ИНГИБИТОРНЫХ БЕЛКОВ (IaIp) ИЗ ПЛАЗМЫ
ATE504649T1 (de)	2011-04-15	Nell-peptidexpressionssysteme und knochenbildende aktivität des nell-peptids
ATE513844T1 (de)	2011-07-15	Acylsulfonamidverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
DE602004018788D1 (de)	2009-02-12	Faktor-ixa-spezifische antikörper, die faktor-viiia-ähnliche wirkung zeigen
EA201690377A1 (ru)	2016-06-30	Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
EA201991409A3 (ru)	2020-01-31	Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
NO20062496L (no)	2006-09-11	Fremgangsmater for behandling av astma
EA201170139A1 (ru)	2011-08-30	5-фенилизоксазол-3-карбоксамиды с противоопухолевыми активностями, модулирующие hsp90
DK1871391T3 (da)	2012-04-16	Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling
EA201001266A1 (ru)	2011-04-29	Эффективные противоопухолевые парамиксовирусы
Ozaki et al.	2019	Isolation and total synthesis of mabuniamide, a lipopeptide from an Okeania sp. marine cyanobacterium
ATE514718T1 (de)	2011-07-15	Peptabody für krebsbehandlung
AR095499A1 (es)	2015-10-21	ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b

Legal Events

Date	Code	Title	Description
2009-06-29	FC2A	Withdrawal, rejection or dismissal of laid open patent application